N
Nam Jin Yoo
Researcher at Catholic University of Korea
Publications - 405
Citations - 13537
Nam Jin Yoo is an academic researcher from Catholic University of Korea. The author has contributed to research in topics: Frameshift mutation & Germline mutation. The author has an hindex of 63, co-authored 403 publications receiving 12692 citations. Previous affiliations of Nam Jin Yoo include Catholic University College, Kensington & The Catholic University of America.
Papers
More filters
Journal ArticleDOI
Altered expression of CDX2 in colorectal cancers.
Byung Jun Choi,Chang Jae Kim,Yong Gu Cho,Jae Hwi Song,Su Young Kim,Suk Woo Nam,Sug Hyung Lee,Nam Jin Yoo,Jung Young Lee,Won Park +9 more
TL;DR: Results indicate that loss of expression of CDX2 protein may play an important role in the tumorigenesis of colorectal cancers and thatCDX2 expression represents a highly significant marker, which is able to identify a subset of patients at high risk.
Journal ArticleDOI
Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase
Sug Hyung Lee,Jong Woo Lee,Young Hwa Soung,Su Young Kim,Suk Woo Nam,Won Sang Park,Sang Ho Kim,Nam Jin Yoo,Jung Young Lee +8 more
TL;DR: Results indicate that MEK is frequently phosphorylated in colorectal tumors, and suggest that phosphorylation of MEK may play a role in the development of coloreCTal tumors.
Journal Article
Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas.
Sug Hyung Lee,Min Sun Shin,Hong Sug Kim,Won Park,Su Young Kim,Hun Kyung Lee,Jik Young Park,Ro Ra Oh,Ja June Jang,Kyung Mi Park,Ji Youn Han,Chang Suk Kang,Jung Young Lee,Nam Jin Yoo +13 more
TL;DR: Data imply that Bcl10 may occasionally be involved in the pathogenesis of lymphoma and GCTs, but the absence or low frequency of the mutation suggests that either B cl10 is inactivated by other mechanisms or it is not the only target of chromosome 1p22 deletion in human tumors.
Journal ArticleDOI
Detection of low-level EGFR T790M mutation in lung cancer tissues.
TL;DR: Oh JE, An CH, Yoo NJ, Lee SH.
Journal ArticleDOI
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer
TL;DR: High HGF levels are significantly associated with resistance to gefitinib and can be used as a predictive marker for the differential outcome of gefithinib treatment in NSCLC irrespective of EGFR mutation status.